Drugs / AZD4248
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07024823 | Jun 2025 → Dec 2026 expected | chronic kidney disease | AstraZeneca | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD4248 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07024823 ↗ |
| Route | Oral | “AZD4248 will be administered orally.” NCT07024823 ↗ |